BioCryst Pharmaceuticals vs Kiniksa Pharmaceuticals International
BCRX and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and KNSA compare
Kiniksa Pharmaceuticals International is the larger company, worth 7.8 times as much as BioCryst Pharmaceuticals ($15.1B against $1.9B).
BioCryst Pharmaceuticals grew revenue faster over the last twelve months (60.3% versus 58.2% for Kiniksa Pharmaceuticals International).
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −37.4% at BioCryst Pharmaceuticals.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | KNSA |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $15.1B |
| Share price | $7.61 | $96.33 |
| Change, 1 year | 6.0% | 137% |
| Change, 5 years | −36.0% | 690% |
| Beta (5Y) | 0.79 | 0.31 |
| Employees | 435 | 366 |
| StockData Score | ||
| Total score | 9 | 14 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 | 4 |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 74.1× |
| P/S | 2.0× (better) | 16.0× |
| P/B | – | 21.3× |
| EV/EBITDA | – | 110× |
| P/FCF | 5.3× (better) | 76.8× |
| FCF yield | 18.8% (better) | 1.3% |
| Fair value | – | $17.17 |
| Margin of safety | – | −461% |
| Growth | ||
| Revenue growth (TTM) | 60.3% (better) | 58.2% |
| Revenue growth, 5Y average | 118% | – |
| Net income growth (TTM) | – | 205% |
| EPS growth (TTM) | – | 189% |
| Profitability | ||
| Gross margin | 97.9% (better) | 90.2% |
| Operating margin | −30.1% | 13.8% (better) |
| Net margin | −37.4% | 11.6% (better) |
| FCF margin | 38.0% (better) | 20.8% |
| Return on equity | – | 17.6% |
| Return on invested capital | – | 60.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −3.8× | – |
| Current ratio | 2.71 | 3.91 (better) |
| Altman Z-score | −3.13 | 34.82 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 29.9% |
| Held by insiders | 1.9% | 5.1% |
| Insider net buying, 12 months | −$4.1M (better) | −$122M |
| Short interest, % of float | 11.0% | 2.9% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.